The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
BSH 2022 | Future developments in myeloma treatment
Sally Moore, MD, Royal United Hospital, Bath, UK, briefly discusses future developments in multiple myeloma (MM) treatment, drawing focus on the use of chimeric antigen receptor T-cell (CAR-T) therapy and bispecific antibodies. Dr Moore also mentions the excitement surrounding other novel agents in myeloma treatment, their increasing efficacy, and the improved management of toxicities. This interview took place at the 62nd Annual Scientific Meeting of the British Society for Haematology (BSH) 2022, in Manchester, UK.
